The company recently raised $8 million and is looking to partner with other firms interested in antigen discovery and diagnostic development.
The companies will evaluate Adaptive's ClonoSeq assay for monitoring minimal residual disease in multiple myeloma patients treated with Janssen's Darzalex.
SerImmune is developing an immune mapping technology that uses next-generation sequencing to identify how circulating antibodies pair with antigens.
In 86 pretreated cancer patients with mismatch repair deficiency, researchers saw objective response rates exceeding 50 percent after anti-PD-1 immunotherapy.
The researchers plan to profile patients with both Adaptive Biotechnologies' ImmunoSeq platform and 10x Genomics' single-cell immune repertoire profiling technology.
Illumina's partnership with the Human Vaccines Project and Vanderbilt looks to crunch data sets billions of times larger than human genome.
The project aims to sequence the immune repertoires of study participants to spur new vaccine and immunotherapy development.
Adaptive aims to commercialize and scale its techniques to identify immune signatures in other infectious diseases, autoimmune disorders, and even cancer.
The single-cell VDJ profiling kit is the first of a suite of immunology products the company plans to launch this year.
The partners will characterize patient immune response to two new investigational immunotherapies from Argos Therapeutics.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.